Pharmaceutical

Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast cancers.

Apr 6, 2025 - 06:00
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast cancers.
Read the original article

Tags:

Previous Article

Uveitis market expected to reach $1.5bn across 7MM by 2033

Next Article

‘Fear and uncertainty’ linger over FDA’s future in wake of Trump admin’s layoffs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rentschler Biopharma and Ikarovec partner to expedite new gene therapies

Rentschler Biopharma and Ikarovec partner to expedite n...

Jun 3, 2023

Biogen and Neomorph enter molecular glue degrader deal

Biogen and Neomorph enter molecular glue degrader deal

Nov 1, 2024

Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial

Eli Lilly’s shares up as oral GLP-1RA scores in first P...

Apr 18, 2025